» Articles » PMID: 30838631

Lipopeptide Delivery of SiRNA to the Central Nervous System

Overview
Specialty Molecular Biology
Date 2019 Mar 7
PMID 30838631
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

RNA interference is a relatively new tool used to silence specific genes in diverse biological systems. The development of this promising new technique for research and therapeutic use in studying and treating neurological diseases has been hampered by the lack of an efficient way to deliver siRNA transvascularly across the blood-brain barrier (BBB) to the central nervous system (CNS). Here we describe the generation of three different liposomal siRNA delivery vehicles to the CNS using the thin film hydration method. Utilizing cationic or anionic liposomes protects the siRNA from serum nucleases and proteases en route. To deliver the siRNA specifically to the CNS, the liposomes are complexed to a peptide that acts as a neuronal address by binding to nicotinic acetylcholine receptors (nAchRs). When injected intravenously, these liposome-siRNA-peptide complexes (LSPCs) or peptide addressed liposome encapsulated therapeutic siRNA (PALETS) resist serum degradation, effectively cross the BBB and deliver siRNA to AchR-expressing cells to suppress protein expression in the CNS.

Citing Articles

The Sirtuin 5 Inhibitor MC3482 Ameliorates Microglia‑induced Neuroinflammation Following Ischaemic Stroke by Upregulating the Succinylation Level of Annexin-A1.

Xia Q, Yu Y, Zhan G, Zhang X, Gao S, Han T J Neuroimmune Pharmacol. 2024; 19(1):17.

PMID: 38717643 DOI: 10.1007/s11481-024-10117-x.


Liposome-Mediated Anti-Viral Drug Delivery Across Blood-Brain Barrier: Can Lipid Droplet Target Be Game Changers?.

Mondal S, Ghosh S Cell Mol Neurobiol. 2023; 44(1):9.

PMID: 38123863 PMC: 11407177. DOI: 10.1007/s10571-023-01443-4.


Multicomponent Lipid Nanoparticles for RNA Transfection.

Gretskaya N, Akimov M, Andreev D, Zalygin A, Belitskaya E, Zinchenko G Pharmaceutics. 2023; 15(4).

PMID: 37111773 PMC: 10141487. DOI: 10.3390/pharmaceutics15041289.


Nanocarriers for Delivery of Oligonucleotides to the CNS.

Male D, Gromnicova R Int J Mol Sci. 2022; 23(2).

PMID: 35054957 PMC: 8775451. DOI: 10.3390/ijms23020760.

References
1.
Harrington K, Lewanski C, Stewart J . Liposomes as vehicles for targeted therapy of cancer. Part 2: clinical development. Clin Oncol (R Coll Radiol). 2000; 12(1):16-24. DOI: 10.1053/clon.2000.9105. View

2.
Harrington K, Rowlinson-Busza G, Syrigos K, Uster P, Abra R, Stewart J . Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: implications for novel targeting strategies. Br J Cancer. 2000; 83(2):232-8. PMC: 2363473. DOI: 10.1054/bjoc.1999.1232. View

3.
Harrington K, Rowlinson-Busza G, Syrigos K, Vile R, Uster P, Peters A . Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res. 2001; 6(12):4939-49. View

4.
Lakkaraju A, Dubinsky J, Low W, RAHMAN Y . Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes. J Biol Chem. 2001; 276(34):32000-7. DOI: 10.1074/jbc.M100138200. View

5.
Paddison P, Caudy A, Hannon G . Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A. 2002; 99(3):1443-8. PMC: 122210. DOI: 10.1073/pnas.032652399. View